Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 24 Nov 2021 for Adamas Pharmaceuticals Inc.
Filing timeline
BuySaleVijay Shreedhar
Insider track record
Disclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Vijay Shreedhar: trading record in brief
Vijay Shreedhar (senior executive) discloses dealings in Adamas Pharmaceuticals Inc to SEC (Form 4). In total, 8 filings cover trades dated from 7 June 2019 to 24 November 2021.
No open-market purchase appears, only 3 sales worth €56k. Outside the open market, there are 4 share grants. 2021 to date brings no purchases and 3 sales.
Most recently, on 24 November 2021, the filings show a transaction in Adamas Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Vijay Shreedhar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
18,750 shares0Common StockSEC:0001328143-21-000090:0
6,200 shares@ US$5.1585100.0% of flowCommon StockSEC:0001328143-21-000067:0
2 of 2 declarations
